Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing of blood thinner injection could prevent artery blockage after heart procedure

NCT ID NCT06890312

Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether giving the blood thinner heparin before inserting a tube into the wrist artery can prevent a common complication: blockage of that artery. About 550 people undergoing a heart procedure through the wrist will be randomly assigned to receive heparin either before or after the tube is placed. The main goal is to see which timing reduces the risk of artery blockage the next day.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
heparin
What this could lead to
If it works, this could lead to a simple change in practice that lowers the risk of radial artery blockage after heart procedures.
What could go wrong
This is a relatively small, early-stage study. The timing change may not reduce blockage rates, and there is always a risk of bleeding with heparin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 550 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention * Subject affiliated to a social protection health insurance * Subject able to understand the objectives and risks of the research and to provide dated and signed consent * Subject who has been informed of the results of the preliminary medical examination Exclusion Criteria: * Contraindication to the use of heparin (history of heparin-induced thrombocytopenia) * Very high bleeding risk defined by recent bleeding (\<6 months) of type 3 of the BARC classification * Subject in an exclusion period (determined by a previous or ongoing study) * Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.) * Subject under safeguard of justice * Subject under guardianship or curatorship * Pregnancy * Breastfeeding * Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anticoagulation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arterial occlusion Arterial Occlusive Diseases Hemorrhage hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anticoagulation Bleeding Coronary angiography Percutaneous coronary intervention Radial artery occlusion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, Bas-Rhin, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.